ProQR Therapeutics (PRQR) Interest Expenses (2013 - 2026)

ProQR Therapeutics has reported Interest Expenses for 12 years, with the latest figure at $55025.0 in Q1 2026.

• Quarterly Interest Expenses fell 75.09% year-over-year to $55025.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 3.03% YoY) and the FY2025 annual result came in at $1.5 million, up 29.33% from the prior year.
• Interest Expenses retreated to $55025.0 in Q1 2026 per PRQR's latest filing, from $2.0 million in the prior quarter.
• Over five years, Interest Expenses peaked at $7.5 million in Q4 2022 and troughed at -$1.3 million in Q2 2022.
• A 4-year average of $775746.4 and a median of $58861.9 in 2025 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 1317.91% in 2022, down 90.62% in 2022.
• Over 4 years, Interest Expenses stood at $7.5 million in 2022, then slumped by 75.99% to $1.8 million in 2024, then rose by 10.49% to $2.0 million in 2025, then tumbled by 97.22% to $55025.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $55025.0, $2.0 million, and -$176527.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.